ArticleJournal of blood medicine2019
Selective purging of human multiple myeloma cells from peripheral blood mononuclear cells: a preliminary study.
Article in Journal of blood medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
- Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients.Blood cancer journal · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-dose chemotherapy followed by autologous peripheral blood stem-cell transplantation are standards of therapy for patients diagnosed with multiple myeloma. The purging process to remove contaminating residual myeloma cells could improve patient outcomes. In this study, a purging method of human multiple myeloma cells from peripheral blood mononuclear cells was evaluated. MATERIALS AND
methodsThe human myeloma cell line RPMI-8226 (Seoul, Korea) was treated with bortezomib (Selleck Chemicals, Houston, TX, USA) or lenalidomide (Sigma Aldrich, St. Louis, MO, USA). The mixture of the human peripheral blood mononuclear cell line PCS-800-011 (ATCC, USA) and RPMI-8226 was treated with bortezomib or lenalidomide for 24 hours. The efficacy of purging myeloma cells was evaluated by 8-color flow cytometric analysis.
resultsThe cytotoxicity of bortezomib (10-160 nmol/L) and lenalidomide (200-3,200 nmol/L) was investigated on RPMI-8226 myeloma cell line. A 24-hour incubation with bortezomib at 10, 20, 40, 80, 160 nmol/L induced 5.45%±0.07%, 47.15%±1.20%, 57.15%±0.21%, 72.35%±0.07%, and 84.75%±0.49% growth inhibition in RPMI-8226 cells, respectively. A 24-hour incubation with lenalidomide at 200, 400, 800, 1,600, and 3,200 nmol/L induced 5.45%±0.07%, 7.55%±0.07%, 9.75%±0.35%, 18.25%±0.21%, and 39.75%±0.78% growth inhibition in RPMI-8226 cells, respectively. Bortezomib (40 nmol/L, 24 hours) and lenalidomide (3,200 nmol/L, 24 hours) effectively removed CD38
conclusionThe results of the present study demonstrated that the bortezomib and lenalidomide treatment in RPMI-8226 multiple myeloma cells effectively removed the contaminated plasma cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.